#News for #Media and #Investors A new therapy for a respiratory disease has received approval today from the US Food and Drug Administration (FDA). For more information, visit: https://t.co/ZYBhm4daCd

#News for #Media and #Investors: Today, we are announcing that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new therapy to treat two respiratory diseases. For more information, visit: https://t.co/8z9eFhfDRj

Human diseases have puzzled researchers for centuries. Through a new collaboration with Cambridge Stem Cell Institute’s Teichmann Laboratory, we’re aiming to demystify them and get ahead of disease together. Read more on how this partnership impacts drug discovery and

#News for #investors and #media: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of two potential biologic treatments across three respiratory conditions today. Read more: https://t.co/kb4nWbLOEt

#News for #investors and #media: The European Medicines Agency’s CHMP have issued a positive opinion on the expansion to a younger population for one of our vaccines. Access our website here: https://t.co/XzoRAHt2kc

#News for #Media and #Investors: Today, we are announcing that one of our oral anti-infectives has been approved by the FDA. Learn more: https://t.co/WmsyOlvJtj

#News for #Investors and #Media: Today we announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: https://t.co/TP9M7dOfyo

Outsmarting cancer demands focus. That’s why we’re channelling our science and technology where it can make the biggest difference for people living with cancer. Find us at #ASH25 this weekend. 🔗 https://t.co/MiqJQlFdwY

Cancer remains one of the world’s leading causes of death – yet people living with difficult-to-treat blood cancers still face limited treatment options. By combining targeted science and innovative tech, we’re working to change that. Learn more: https://t.co/fFvT8xcg0q #ASH25

Big news for U.S. innovation! We've officially opened our new Vaccine & Infectious Disease R&D HQ in Boston's Cambridge Park Drive. This expanded space is central to our 5-year investment in the U.S., driving faster, better innovation for patients globally.

We’re looking forward to being on the ground at #ASH25 to present our latest progress in blood cancer research. What are you most excited for during ASH 2025? 👇

What does "early" intervention truly mean for lupus patients? Dr. Roger A. Levy explores how providers and patients often have different interpretations and how we can bridge this gap to optimise treatment. Follow the discussion: https://t.co/rYTzkAKn0t

Our response to today's UK-US pharmaceuticals deal:

#News for #investors and #media: We are pleased to present new data from our #bloodcancer pipeline and portfolio at #ASH25. Learn more: https://t.co/cHKt60opS9

Since 2000, we have partnered with the @WHO on the Global Programme to Eliminate Lymphatic Filariasis. 25 years on, we remain committed to helping prevent lymphatic filariasis in endemic countries: https://t.co/nCylqy5fLV

#News for #investors and #media: We’ve announced a collaboration with LTZ Therapeutics to advance up to four oncology therapies targeting haematologic cancers and solid tumours. https://t.co/56ffdlMTBf

We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions. Find out more:

#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC. We remain committed to addressing the global burden of liver disease. Learn more: https://t.co/vx8j1dnltk

Take a look at the highlights from our Q3 2025 performance 👇 More information for media and investors: https://t.co/rFiefkxAm4 $GSK #Q3Results #Earnings

#Investors: Join our CEO Emma Walmsley and other members of our leadership team for our Q3 2025 results webcast at 12:00 GMT, 08:00 EDT. $GSK #Q3Results